The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates

Journal of Bone and Mineral Research

Volumn 14, Issue 5, 1999, Pages 722-729

  Van Beek, Ermond ^a   Löwik, Clemens ^a   Van Der Pluijm, Gabri ^a   Papapoulos, Socrates ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COMPACTIN; ETIDRONIC ACID; FARNESOL; IBANDRONIC ACID; NITROGEN; OLPADRONIC ACID; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE GROWTH; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPLANT; FETUS DEVELOPMENT; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION;

ANIMALS; BONE AND BONES; BONE RESORPTION; CULTURE TECHNIQUES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LOVASTATIN; MEVALONIC ACID; MICE; MODELS, CHEMICAL; NITROGEN; PREGNANCY; PROTEIN ISOPRENYLATION;

EID: 0345161422     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.5.722     Document Type: Article

References (32)

1. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA (eds.) Bone and Mineral Research, Vol. 8. Elsevier Science BV, Amsterdam, the Netherlands, pp. 265-306.
2. Rogers MJ, Watts DJ, Russel RGG 1997 Overview of bisphosphonates. Cancer 15 (Suppl):1652-1660.
3. Rodan GA, Fleisch HA 1996 Bisphosphonates: Mechanisms of action. J Clin Invest 97:2692-2696.
4. Fleisch HA 1998 Bisphosphonates: Mechanisms of action. Endoer Rev 19:80-100.
5. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH 1992 Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663.
6. Amin D, Cornell SA, Bilder GE 1996 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittel-Forsch 46:759-762.
7. Abe I, Tomesch JC, Wattanasin S, Pretwich GD 1994 Inhibitors of squalene biosynthesis and metabolism. Nat Prod Rep 11:279-302.
8. Casey PJ 1992 Biochemistry of protein prenylation. J Lipid Res 33:1731-1740.
9. Luckman SP, Huges DE, Coxon FP, Russel RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581-589.
10. Boonekamp PM, van der Wee-Pals LJA, Wijk-van Lennep MML, Thesingh CW, Bijvoet OLM 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39.
11. Papapoulos SE, Hoekman K, Löwik CWGM, Vermij P, Bijvoet OLM 1989 Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 5:775-781.
12. Boonekamp PM, Löwik CWGM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Bijvoet OLM 1987 Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 2:29-42.
13. van Beek E, van Hoekstra M, de Ruit M, Löwik C, Papapoulos S 1994 Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875-1882.
14. Papapoulos SE 1996 Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kesey J (eds.) Osteoporosis. Academic Press, San Diego, CA, U.S.A., pp. 1209-1234.
15. Crick DC, Andres DA, Waechter CJ 1995 Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells. Biochem Biophys Res Commun 211:590-599.
16. Crick DC, Waechter CJ, Andres DA 1994 Utilization of geranylgeraniol for protein isoprenylation in C6 Glial cells. Biochem Biophys Res Commun 205:955-961.
17. van der Pluijm G, Most W, van der Wee-Pals L, de Groot H, Papapoulos S, Löwik C 1991 Two distinct effects of recombinant human tumor necrosis factor-α on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 129:1596-1604.
18. Scheven BAA, Kawilarang-de Haas EWM, Wassenaar AM, Nijweide PJ 1986 Differentiation kinetics of osteoclasts in the periosteum of embryonic long bones in vivo and in vitro. Anat Rec 214:418-423.
19. Haug JS, Goldner CM, Yazolovitskaya EM, Voziyan PA, Melnykovych G 1994 Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: Effect of phosphatidylcholine. Biochim Biophys Acta 1223:133-140.
20. Voziyan PA, Haug JS, Melnykovych G 1995 Mechanism of farnesol cytotoxicity: Further evidence for the role of PKC-dependent signal transduction in farnesol-induced apoptotic cell death. Biochem Biophys Res Commun 212:479-486.
21. Miquel K, Pradines A, Favre G 1996 Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 225:869-876.
22. Crick DC, Andres DA, Waechter CJ 1997 Geranylgeraniol promotes entry of UT-2 cells into the cell cycle in the absence of mevalonate. Exp Cell Res 231:302-307.
23. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR 1997 Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 82:1434-1439.
24. Ghosh PM, Mott GE, Ghosh-Choudhury N, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI 1997 Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim Biophys Acta 1359:13-24.
25. Ericsson J, Runquist M, Thelin A, Andersson M, Chojnacki T, Dallner G 1993 Distribution of Prenyltiansferases in rat tissues. J Biol Chem 268:832-838.
26. Fisher JE, Reszka AA, Masarachia PJ, Rodan GA 1998 Mevalonic acid suppresses lovastatin-and Alendronate-mediated inhibition of osteoclastogenesis. Bone 22 (Suppl):46S (abstract).
27. Reitsma PH, Teitelbaum ST, Bijvoet OLM, Kahn AJ 1982 Differential action of the bisphosphonates (3-amino-1-hydroxy propylidene) -1,1-bisphosphonate (APD) and disodium dichloro methylene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 70:927-933.
28. Rogers MJ, Xiaohui JI, Russel RGG, Blackburn GM, Williamson MP, Bayless AV, Ebetino FH, Watts DJ 1994 Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 303:303-311.
29. Frith JC, Mönkkönen J, Blackburn GM, Russel RGG, Rogers MJ 1997 Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′ (β,γ-dichloromethylene) triphosphate, by mammalian cells in vito. J Bone Miner Res 12:1358-1367.
30. Zhang D, Udagawa N, Nakamura I, Murakami H, Sato S, Yamasaki K, Shibasaki Y, Morii Y, Narumiya S, Takahashi N 1995 The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeltal organization in osteoclasts. J Cell Sci 108:2285-2292.
31. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
32. Babb SG, Kamioka H, Duong LT, Rodan GA, Lim SS 1998 Effects of alendronate on osteoclast morphology and cytoskeleton. Bone 22 (Suppl):45S.